Overview

This trial is active, not recruiting.

Conditions neuroendocrine tumors, carcinoid tumor
Treatment rad001 (everolimus, afinitor®)
Phase phase 1/phase 2
Sponsor Guangdong General Hospital
Collaborator Novartis
Start date July 2010
End date January 2012
Trial size 20 participants
Trial identifier NCT01175096, CRAD001KCN01

Summary

RAD001 continues to be investigated as an anticancer agent on new indications such as neuroendocrine tumors (incl. carcinoid), breast cancer, liver cancer, gastric cancer and lymphoma based on its potential to act:

- directly on the tumor cells by inhibiting tumor cell growth and proliferation

- indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity and VEGF production and VEGF-induced proliferation of endothelial cells)

A role for RAD001 in combination with Sandostatin LAR® Depot in the treatment of advanced carcinoid tumor is suggested by data on the regulatory role of mTOR in cell growth and protein translation and the finding that somatostatin-induced growth arrest is mediated in part by inhibition of the PI3K pathway (Charland, et al. 2001).

The present study is designed to collect safety/tolerability data and evidences for efficacy of RAD001 in the medically highly unmet indication of advanced pulmonary neuroendocrine tumor in Chinese patients.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Active Comparator)
2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day Dose level modifications/interruptions must follow guidelines. One treatment cycle consists of 28 days.
rad001 (everolimus, afinitor®) RAD001
RAD001 will be provided by Novartis to the study sites. RAD001 is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 30 tablets. The study site will dispense an adequate supply of RAD001 to the patient for self-administration at home. 2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day, One treatment cycle consists of 28 days.

Primary Outcomes

Measure
Safety and tolerability
time frame: 28 ±4 days

Secondary Outcomes

Measure
Tumor response
time frame: 6-week

Eligibility Criteria

Male or female participants at least 18 years old.

For carcinoid tumor Inclusion Criteria: - Histologically confirmed carcinoid tumors - Newly diagnosed advanced carcinoid tumors - Measurable tumors - Chinese men and women, age ≥ 18 years - ECOG performance status ≤ 2 - Written informed consent obtained Exclusion Criteria: - Patients with either clinically apparent central nervous system metastases or carcinomatous meningitis(non-clinical symptoms with brain lesions is eligible) - Received Cytotoxic chemotherapy, immunotherapy or radiotherapy prior to enrollment - Patients with a concurrent malignancy, or history of prior malignancy within the past three years, except for basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, treated early stage (T1a) prostate cancer or treated early stage (DCIS or LCIS) breast cancer - Prior therapy with RAD001 or other mTOR inhibitors (sirolimus, temsirolimus, everolimus) - Major surgery in the past two weeks - Any medical condition resulting in >CTC grade 2 dyspnea - Patients with recent hemoptysis associated with carcinoid tumor (> 1 teaspoon in a single episode within 4 weeks) - Serious, severe or uncontrolled medical or psychiatric condition - Patients receiving chronic treatment with corticosteroids or another immunosuppressive agent - Patients with a known history of HIV seropositivity - Women of childbearing potential must have had a negative serum pregnancy test within 3 days prior to the administration of RAD001 - Patients who have received an investigative drug or therapy within the last 30 days For adenocarcinoma and Large cell lung cancer with significant neuroendocrine carcinoma characteristics Inclusion Criteria: - Histologically confirmed locally unresectable or advanced well differentiated (adenocarcinoma,squamous cancer and large cell lung cancer )with significant neuroendocrine carcinoma characteristics tumors : CgA and/or Synaptophysin +(at least 10% of cells that would have to be positive ).( the pathology shows a neuroendocrine component histologically should be at least 10% of tissue within the specimen that is read as "neuroendocrine component"). - Measurable tumors - Patients with newly diagnosed advanced cancer or progressed after 1st line treatment is eligible - Chinese men and women, age ≥ 18 years - ECOG performance status ≤ 2 - Written informed consent obtained Exclusion Criteria: - Patients with either clinically apparent central nervous system metastases or carcinomatous meningitis(non-clinical symptoms with brain lesions is eligible) - Radiotherapy to primary tumor in lung lesions prior to enrollment - Patients with a concurrent malignancy, or history of prior malignancy within the past three years, except for basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, treated early stage (T1a) prostate cancer or treated early stage (DCIS or LCIS) breast cancer - Prior therapy with RAD001 or other mTOR inhibitors (sirolimus, temsirolimus, everolimus) - Major surgery in the past two weeks - Any medical condition resulting in > CTC grade 2 dyspnea - Patients with recent hemoptysis associated with carcinoid tumor (> 1 teaspoon in a single episode within 4 weeks) - Serious, severe or uncontrolled medical or psychiatric condition - Patients receiving chronic treatment with corticosteroids or another immunosuppressive agent - Patients with a known history of HIV seropositivity - Women of childbearing potential must have had a negative serum pregnancy test within 3 days prior to the administration of RAD001 - Patients who have received an investigative drug or therapy within the last 30 days

Additional Information

Official title A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Principal investigator Yilong Wu, MD.PhD
Description The purpose of this phase I b study is to characterize the safety, tolerability, and efficacy of 10 mg RAD001 administered orally on a continuous once-daily dosing regimen in the treatment of advanced pulmonary neuroendocrine tumor. The neuroendocrine tumors arising from bronchi and lung account for 30% of all carcinoid tumors, and there are a lot of well differentiated adenocarcinoma, squamous cancer and large cell lung cancer with significant neuroendocrine carcinoma characteristics who seems had a similarly prognosis with carcinoid tumor. There is no effective treatment available for advanced pulmonary NETs at this time. The rationale for this study is based on both preclinical and clinical considerations. IGF-1 is a known autocrine regulator of CgA secretion and cell growth in human neuroendocrine tumor cells (von Wichert, et al. 2000; Wulbrand, et al. 2000; Van Gompel and Chen 2004). A role for RAD001 as monotherapy in carcinoid and pancreatic NET is suggested by the regulatory role of mTOR in cell growth, metabolism and protein translation (Fingar and Blenis 2004; Vignot, et al. 2005) and the Novartis observation that the PI3K/mTOR pathway is activated by IGF-1 in carcinoid and pancreatic NET cells (von Wichert, et al. 2000; Van Gompel and Chen 2004). The proposed RAD001 dosage regimen is 10 mg/day in both monotherapy and combination therapy settings. This regimen is based both on Novartis Phase I/II studies and on results from an investigator-sponsored study in NET. Initial Phase I studies of the RAD001 10 mg/day schedule demonstrated dose limiting toxicities in 2 of 12 patients. Tolerability of this schedule was verified in a total of 33 patients in Phase 1 studies as well as in 12 breast cancer patients treated with letrozole 2.5 mg plus RAD001 10 mg/day. Pharmacodynamic modeling indicates that downstream effectors of mTOR are completely suppressed by RAD001 at the 10 mg/day dose. No increased toxicity is expected from use of RAD001 in combination with Sandostatin LAR® Depot. The investigator-sponsored study in NET, toxicity observed with RAD001 5 mg/day in combination with Sandostatin LAR® Depot was similar to that observed for RAD001 5 mg/day alone in Phase 1 studies (Yao, et al. 2006). Therefore a dose of RAD001 10 mg/day will be evaluated in this study.
Trial information was received from ClinicalTrials.gov and was last updated in August 2010.
Information provided to ClinicalTrials.gov by Guangdong General Hospital.